Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
NUT carcinoma is a rare disease that is often resistant to treatment. There is no United States Food and Drug Administration (US FDA) approved standard treatment or optimal regimen that has been identified for NUT carcinoma. However, patients may still benefit from widely available chemotherapy regimens, radiation therapy, surgery, and/or participation in clinical trials testing promising targeted agents for NUT carcinoma.
Your NUT carcinoma treatment team will develop a personalized treatment plan based on you and your needs. Our specialists work closely together and collaborate regularly to ensure that your care plan offers the best possible outcomes. We encourage you to be actively involved in the decision-making process.
Your treatment plan may include:
The right treatment plan for you depends on many factors, including the size and location of the tumors.
Dana-Farber/Harvard Cancer Center (DF/HCC) offers one of the largest and most active clinical trial programs available, including trials for people with NUT carcinoma. We encourage our patients' participation in clinical trials. For some people with advanced or recurrent cases of NUT carcinoma, taking part in a clinical trial may be the best treatment option.
NUT carcinoma is an area of active research and DF/HCC is leading the way in developing new treatment approaches. If you qualify for a clinical trial, your doctor and treatment team will discuss all the options and risks associated with clinical trial participation.
If you are a referring physician and have a patient with NUT carcinoma, we look forward to working with you. Find out more about referring a patient.
Pathology consultation is also available for help with initial diagnosis of NUT carcinoma via the International NUT Midline Carcinoma Registry.
The International NUT Midline Carcinoma Registry works to collect data on patients with NUT carcinoma. This data is crucial for supporting future research and paving the way for scientific discoveries regarding the diagnosis. Patients of all ages from anywhere in the world may participate. For more information or to enroll, please visit the registry website.
To address all of your physical and emotional needs, we provide a comprehensive range of support services and integrative therapies. Among our many services, we offer individual and family counseling, physical therapy, pain and symptom management, acupuncture, massage, Reiki, and support groups.
New Patient Appointments 877-442-3324
New Pediatric Patient Appointments 617-632-5508
Clinical Trials Questions?
877-DF-TRIAL (877-338-7425)
Dana-Farber Centers with NUT Carcinoma Specialists
Thoracic (Lung) Cancer Treatment CenterHead and Neck Cancer Treatment CenterChildhood Solid Tumor Center